Localization of receptors for vasoactive intestinal peptide, somatostatin, and substance P in distinct compartments of human lymphoid organs

Blood

Volumn 92, Issue 1, 1998, Pages 191-197

  Reubi, Jean Claude ^a   Horisberger, Ursula ^a   Kappeler, Andreas ^a   Laissue, Jean A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; SUBSTANCE P; SUBSTANCE P RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

APPENDIX; ARTICLE; AUTORADIOGRAPHY; GERMINAL CENTER; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; LYMPH FOLLICLE; LYMPH NODE; LYMPHOID ORGAN; PALATINE TONSIL; PEYER PATCH; PRIORITY JOURNAL; PROTEIN LOCALIZATION; THYMUS;

EID: 0032126640     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.1.191.413k12_191_197     Document Type: Article

References (40)

1. O'Dorisio MS: Neuropeptide modulation of the immune response in gut associated lymphoid tissue. Int J Neurosci 38:189, 1988
2. Bellinger DL, Lorton D, Brouxhon S, Feiten S, Feiten DL: The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv Neuroimmunol 6:5, 1996
3. Ottaway C: Vasoactive intestinal peptide and immune function, in Ader R, Feiten DL, Cohen N (eds): Psychoneuroimmunology. Orlando, FL, Academic, 1991, p 225
4. Reubi JC, Horisberger U, Waser B, Gebbers JO, Laissue J: Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology 103:1207, 1992
5. Robberecht P, Gourlet P, Vertongen P, Svoboda M: Characterization of the VIP receptor from SUP T1 lymphoblasts, Adv Neuroimmunol 6:49, 1996
6. Ottaway CA, Lay TE, Greenberg GR: High affinity specific binding of vasoactive intestinal peptide to human circulating T cells, B cells and large granular lymphocytes. J Neuroimmunol 29:149, 1990
7. Ottaway CA: Insertion and internalization of vasoactive intestinal peptide (VIP) receptors in murine CD4 T lymphocytes. Regul Pept 41:49, 1992
8. Waschek JA, Bravo DT, Richards ML: High levels of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor mRNA expression in primary and tumor lymphoid cells. Regul Pept 60:149, 1995
9. McGillis JP, Organist ML, Scriven KH, Payan DG: Purification of the 33,000-dalton ligand binding-protein constituent of the lymphoblast substance P receptor. J Neurosci Res 18:190, 1987
10. Sreedharan SP, Kodama KT, Peterson KE, Goetzl EJ: Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem 264:949, 1989
11. Fais S, Annibale B, Boirivant M, Santoro A, Pallone F, Delle Fave G: Effects of somatostatin on human intestinal lamina propria lymphocytes. Modulation of lymphocyte activation. J Neuroimmunol 31:211, 1991
12. Scicchitano R, Dayin P, Bienenstock J, Payan DG, Stanisz AM: Distribution of somatostatin receptors on murine spleen and Peyer's patch T and B lymphocytes. Brain Behav Immun 1:173, 1987
13. Stanisz AM, Scicchitano R, Payan DG, Bienenstock J: In vitro studies in immunoregulation by substance P and somatostatin. Ann N Y Acad Sci 496:217, 1987
14. Payan DG, Hess CA, Goetzl EJ: Inhibition by somatostatin of the proliferation of T-lymphocytes and Molt-4 lymphoblasts. Cell Immunol 84:433, 1984
15. Pawlikowski M, Stepien H, Kunert-Radek J, Serially AV: Effect of somatostatin on the proliferation of mouse spleen lymphocytes in vitro. Biochem Biophys Res Commun 129:52, 1985
16. Kimata H, Yoshida A, Ishioka C, Mikawa H: Differential effect of vasoactive intestinal peptide, somatostatin, and substance P on human IgE and IgG subclass production. Cell Immunol 144:429, 1992
17. Kimata H, Yoshida A, Fujimoto M, Mikawa H: Effect of vasoactive intestinal peptide, somatostatin, and substance P on spontaneous IgE and IgG4 production in atopic patients. J Immunol 150:4630, 1993
18. Hinterberger W, Cerny C, Kinast H, Pointner H, Tragl KH: Somatostatin reduces the release of colony-stimulating activity (CSA) from PHA-activated mouse spleen lymphocytes. Experientia 34:860, 1978
19. Pascual DW, Xu-Amano J, Kiyono H, McGhee JR, Bost KL: Substance P acts directly upon cloned B lymphoma cells to enhance IgA and IgM production. J Immunol 146:2130, 1991
20. Nio DA, Moylan RN, Roche JK: Modulation of T lymphocyte function by neuropeptides. J Immunol 150:5281, 1993
21. Tang SC, Braunsteiner H, Wiedermann CJ: Regulation of human T lymphoblast growth by sensory neuropeptides: Augmentation of cholecystokinin-induced inhibition of Molt-4 proliferation by somato- statin and vasoactive intestinal peptide in vitro. Immunol Lett 34:237, 1992
22. Carr DJJ: Neuroendocrine peptide receptors on cells of the immune system, in Blalock JE (ed): Neuroimmunoendocrinology, vol 52. Basel, Switzerland, Karger, 1992, p 84
23. Stanisz AM, Befus D, Bienenstock J: Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferation by lymphocytes from Peyer's patches, mesenteric lymph nodes, and spleen. J Immunol 136:152, 1986
24. Payan DG, Goetzl EJ: Modulation of lymphocyte function by sensory neuropeptides. J Immunol 135:7835, 1985
25. Hermann GE, O'Dorisio MS: Modulation of IgA synthesis by neuroendocrine peptides. Trends Endocrinol Metab 2:68, 1991
26. Reisine T, Bell GI: Molecular biology of somatostatin receptors. Endocr Rev 16:427, 1995
27. Wank SA: Cholecystokinin receptors. Am J Physiol 269:G628, 1995
28. Harmar T, Lutz EM: Multiple receptors for PACAP and VIP. Trends Neurosci 15:97, 1994
29. Maggi CA: The mammalian tachykinin receptors. Gen Pharmacol 26:911, 1995
30. Reubi JC: In vitro identification of vasoactive intestinal peptide receptors in human tumors: Implications for tumor imaging. J Nucl Med 36:1846, 1995
31. Arimura A: Receptors for pituitary adenylate cyclase-activating polypeptide. Comparison with vasoactive intestinal peptide receptors. Trends Endocrinol Metab 3:288, 1992
32. Reubi JC, Kvols LK, Waser B, Nagorney D, Heitz PU, Charboneau JW, Reading CC, Moertel C: Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 50:5969, 1990
33. Hennig IM, Laissue JA, Horisberger U, Reubi JC: Substance P receptors in human primary neoplasms: Tumoural and vascular localisation. Int J Cancer 61:786, 1995
34. Reubi JC, Waser B, Läderach U, Stettier C, Friess H, Halter F, Schmassmann A: Localization of cholecystokinin A and cholecystokinin B/gastrin receptors in the human stomach and gallbladder. Gastroenterology 112:1197, 1997
35. Reubi JC, Schaer JC, Waser B: Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 57:1377, 1997
36. Abbas AK, Lichtman AH, Pober JS: Cellular and Molecular Immunology (ed 2nd). Philadelphia, PA, Saunders, 1994
37. Calvo JR, Guerrero JM, Molinero P, Blasco R, Goberna R: Interaction of vasoactive intestinal peptide (VIP) with human peripheral blood lymphocytes: Specific binding and cyclic AMP production. Gen Pharmacol 17:185, 1986
38. Reubi JC, Waser B, Horisberger U, Krenning E, Lamberts SWJ, Gebbers JO, Gersbach P, Laissue JA: In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood 82:2143, 1993
39. Tang SC, Fend F, Müller L, Braunsteiner H, Wiedermann CJ: High-affinity substance P binding sites of neurokinin-1 receptor type autoradiographically associated with vascular sinuses and high endothelial venules of human lymphoid tissues. Lab Invest 69:86, 1993
40. Madden KS, Felten DL: Experimental basis for neural-immune interactions. Physiol Rev 75:77, 1995